Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...

Dupilumab and upadacitinib were associated with greater improvements in AD severity when compared with methotrexate, cyclosporine, and phototherapy.

Web-based stress management for newly diagnosed cancer patients (STREAM): A randomized, wait-list controlled intervention study. Adverse health outcomes in relationship to hypogonadism (HG) after ...

BIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASI Using the EASI scale, 100% of patients showed clinically relevant improvement >50% compared to Day 1 during ...

Lorazepam as an adjuvant to haloperidol for agitated delirium at the end of life: A double-blind randomized controlled trial. Effect of inpatient palliative care during hematopoietic stem cell ...